Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock

Posted by Brian Himes on Aug 16th, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) CEO Yu-Hsin Lin sold 365 shares of Belite Bio stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total transaction of $65,827.75. Following the sale, the chief executive officer owned 170,569 shares of the company’s stock, valued at approximately $30,762,119.15. The trade was a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Belite Bio Price Performance

BLTE opened at $162.80 on Friday. The stock has a market cap of $6.53 billion, a P/E ratio of -59.63 and a beta of -1.22. The stock’s 50 day simple moving average is $152.50 and its 200 day simple moving average is $159.86. Belite Bio, Inc. Sponsored ADR has a 1-year low of $60.00 and a 1-year high of $200.00.

Belite Bio (NASDAQ:BLTE – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. Research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BLTE. Zacks Research upgraded Belite Bio from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a research report on Monday, July 6th. Mizuho set a $220.00 price objective on shares of Belite Bio in a research note on Friday. Benchmark restated a “buy” rating on shares of Belite Bio in a report on Friday. Finally, HC Wainwright lifted their target price on shares of Belite Bio from $200.00 to $214.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $205.80.

Read Our Latest Stock Analysis on Belite Bio

Key Headlines Impacting Belite Bio

Here are the key news stories impacting Belite Bio this week:

Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

Institutional Trading of Belite Bio

A number of hedge funds have recently bought and sold shares of BLTE. Royal Bank of Canada grew its stake in Belite Bio by 7.9% in the 1st quarter. Royal Bank of Canada now owns 2,257 shares of the company’s stock worth $360,000 after acquiring an additional 165 shares during the period. Bank of America Corp DE lifted its stake in shares of Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after purchasing an additional 257 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after purchasing an additional 282 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Belite Bio during the fourth quarter worth $103,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Belite Bio in the fourth quarter valued at $108,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.